학술논문
A Metastatic Cervical Adenocarcinoma Patient Carrying HER2 G292R Achieved Complete Response Upon Pyrotinib Treatment
Document Type
article
Source
OncoTargets and Therapy, Vol Volume 14, Pp 4833-4836 (2021)
Subject
Language
English
ISSN
1178-6930
Abstract
Jing Liu,1,* Yanhong Zhuo,2,* Feng Wang,3,* Zirong Li,4,* Yibin Lin,1 Li Li,1 Junping Pan,5 Yanwen Song,5 Haiwei Du,6 Chanhe Li,7 Qin Xu1 1Department of Gynecology, Fujian Medical University Cancer Hospital & Fujian Cancer Hospital, Fuzhou, People’s Republic of China; 2Department of Radiotherapy, Zhangzhou Hospital & Teaching Hospital of Fujian Medical University, Zhangzhou, People’s Republic of China; 3Department of Outpatient, Fujian Hospital of People’s Armed Police, Fuzhou, People’s Republic of China; 4Department of Radiation Oncology, Longyan First Hospital Affiliated to Fujian Medical University, Longyan, People’s Republic of China; 5Department of Radiotherapy, Fujian Medical University Cancer Hospital & Fujian Cancer Hospital, Fuzhou, People’s Republic of China; 6Department of Data Science, Burning Rock Biotech, Guangzhou, People’s Republic of China; 7Department of Medicine, Burning Rock Biotech, Guangzhou, People’s Republic of China*These authors contributed equally to this workCorrespondence: Qin XuDepartment of Gynecology, Fujian Medical University Cancer Hospital & Fujian Cancer Hospital, No. 420 Fuma Road, Fuzhou, 350014, Fujian, People’s Republic of ChinaEmail xuqin772836@163.comAbstract: Cervical cancer patients who develop distant metastasis are rarely curable with very limited treatment options. Chemotherapy is often administered but with limited efficacy. Immunotherapy and anti-angiogenesis therapy are recommended for selected cases of recurrent or metastatic cervical cancers. The clinical efficacy of inhibitors targeting HER2, a commonly mutated gene in cervical cancer, has not been elucidated. Herein, we report a metastatic cervical adenocarcinoma patient carrying HER2 G292R who benefited from pyrotinib after progression on radio-chemotherapy, achieving complete response (CR) with a progression-free survival of 25 months and counting. Our study sheds light on the treatment options for previously treated metastatic cervical adenocarcinoma patients harboring activating HER2 mutations.Keywords: cervical cancer, adenocarcinoma, HER2, pyrotinib, complete response